Tables A13-A16. Impact of α0 and ω on the operating characteristics for scenarios S25 to S32 when there is a conflict in terms of the underlying survival distribution between historical and new data. These tables describe the impact of α0 and ω on the operating characteristics in case of a conflict in terms of survival distribution between historical and new data. Tables A13 and A14 describe results for scenarios S25 to S28 when the historical data follow a Weibull distribution, the new data follow a piecewise exponential distribution, and data are analysed using either a Bayesian Weibull model (Table A13) or a Bayesian piecewise exponential model (Table A14). Tables A15 and A16 describe results for scenarios S29 to S32 when the historical ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...
Tables A1-A3. Impact of α0 and ω on the operating characteristics for scenarios S1 to S12. These tab...
Tables A7-A12. Impact of α0 and ω on the operating characteristics for scenarios S1 to S12 when σ H ...
Figure A4-A6. Graphical representation of scenarios S1 to S32. Graphical representations of scenario...
Likelihood of the distributions used. Description of the likelihood of a Weibull proportional hazard...
Figure A7. Posterior distribution of the log-hazard ratio depending on the values of the weighting p...
Figure A3. Historical datasets considered in the simulation study. Observed Kaplan-Meier curves of S...
Figure A1. Mixture prior distribution of the treatment effect for different values of ω. Mixture pri...
R code of to compute the posterior joint distribution in the context of a Bayesian Weibull model (PD...
Figure A2. Subgroup of OS2006 historical data (SARC-OS data). Observed Kaplan-Meier and parametric e...
Motivating example: the Sarcome-13 trial. Context and design of the Sarcome-13 trial. This document ...
Table S1. TPR, FPR and FDR in variable selection with 50 replications (Weibull distribution). Table ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...
Tables A1-A3. Impact of α0 and ω on the operating characteristics for scenarios S1 to S12. These tab...
Tables A7-A12. Impact of α0 and ω on the operating characteristics for scenarios S1 to S12 when σ H ...
Figure A4-A6. Graphical representation of scenarios S1 to S32. Graphical representations of scenario...
Likelihood of the distributions used. Description of the likelihood of a Weibull proportional hazard...
Figure A7. Posterior distribution of the log-hazard ratio depending on the values of the weighting p...
Figure A3. Historical datasets considered in the simulation study. Observed Kaplan-Meier curves of S...
Figure A1. Mixture prior distribution of the treatment effect for different values of ω. Mixture pri...
R code of to compute the posterior joint distribution in the context of a Bayesian Weibull model (PD...
Figure A2. Subgroup of OS2006 historical data (SARC-OS data). Observed Kaplan-Meier and parametric e...
Motivating example: the Sarcome-13 trial. Context and design of the Sarcome-13 trial. This document ...
Table S1. TPR, FPR and FDR in variable selection with 50 replications (Weibull distribution). Table ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...
International audienceBACKGROUND:Performing well-powered randomised controlled trials (RCTs) of new ...